Farallon Capital Management 13F: New $81M Stake in DNTH

Farallon Capital Management Acquires 836,000 Shares of Dianthus Therapeutics, Inc.

Farallon Capital Management launched a major new investment in Dianthus Therapeutics, Inc. (NasdaqCM: DNTH) during the period, adding 836,000 shares to its portfolio. The newly initiated stake carried an estimated value of $81.49 million based on the recent filing details. Because form 13F regulatory filings look backward at institutional holdings from the end of the reporting period, this snapshot may not reflect the fund's exact share count today.

## Dianthus Therapeutics Stock Performance and Recent Trading

The biotech company's shares traded near $97.48 ahead of this report. The stock has experienced a wide trading range over the past year, dropping as low as $32.22 while climbing up to $117.88. Its current price sits comfortably above its 200-day moving average of $79.04, reflecting solid momentum leading into the latter half of the year.

## Wall Street Analysts Update Outlook and Price Targets

Market experts have closely tracked the clinical-stage biotech firm's progress with several fresh updates. On October 15, 2026, HC Wainwright & Co. kept a buy rating on the stock with a price target of $158.00. Earlier in the autumn, JP Morgan initiated coverage on September 11, 2026, with an overweight rating and a $135.00 price target. Citigroup also began coverage on September 4, 2026, assigning a buy rating and a $156.00 target. Additional updates came during August 2026, when Truist Securities adjusted its target to $128.00, Wedbush set an outperformance target of $122.00, and Evercore ISI Group moved its target to $134.00. Overall, fifteen analysts share a strong buy consensus for the company, pointing to a mean target price of $140.80.

## Inside Dianthus Therapeutics Operations

Dianthus Therapeutics, Inc. is a New York-based biotechnology enterprise focused on developing novel treatments for patients suffering from severe autoimmune conditions. The clinical-stage firm relies on its proprietary antibody engineering to target specific complement proteins and receptors involved in immune disorders. With a team of 92 employees, the company continues advancing its pipeline toward future clinical milestones.

## What to Watch Next for Dianthus Therapeutics

Investors tracking the biotech firm will look toward the upcoming financial disclosures and clinical updates for further direction. The company's next earnings report is scheduled for November 5, 2026. Future regulatory filings will also show whether major institutional backers like Farallon Capital Management adjust their positions further as clinical trials progress.